Literature DB >> 10227083

The effects of dopamine D2 and D3 antagonists on spontaneous motor activity and morphine-induced hyperactivity in male mice.

C Manzanedo1, M A Aguilar, J Miñarro.   

Abstract

RATIONALE: Dopaminergic neurotransmission, in particular the mesolimbic pathway, is involved in spontaneous locomotor activity and in morphine-induced hyperactivity, since the drugs acting on DA receptors can modify the action of morphine and this effect could be dependent on the type of DA receptor affected.
OBJECTIVE: In this study, the action of U-99194A maleate, haloperidol, sulpiride and morphine (5, 10, 20, 40 mg/kg) on locomotor activity in male mice was evaluated. Likewise, the effects of these dopaminergic antagonists on morphine-induced hyperactivity were studied.
METHODS: Animals treated with U-99194A maleate (2.5, 5, 10, 20 mg/kg), haloperidol (0.075, 0.1 mg/kg), sulpiride (20, 40 mg/kg), or morphine (5, 10, 20, 40 mg/kg), and animals treated with these neuroleptics plus morphine were tested in an actimetre at different time points.
RESULTS: It was found that an increase in locomotor activity was produced between 0 and 30 min after the administration of 20 mg/kg U-99194A maleate and between 30 and 60 min after the administration of 20 and 40 mg/kg morphine. This dose of U-99194A maleate and the high dose of sulpiride reverts the hyperactivity induced by 20 mg/kg morphine. Haloperidol reversed the hyperactivity induced by all doses of morphine.
CONCLUSIONS: Our results confirm that the action of DA D2 and D3 receptors could be dependent on the dopaminergic state, in this case modified by the action of morphine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10227083     DOI: 10.1007/s002130050922

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

Review 1.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

2.  Loss of β-arrestin2 in D2 cells alters neuronal excitability in the nucleus accumbens and behavioral responses to psychostimulants and opioids.

Authors:  Kirsten A Porter-Stransky; Alyssa K Petko; Saumya L Karne; L Cameron Liles; Nikhil M Urs; Marc G Caron; Carlos A Paladini; David Weinshenker
Journal:  Addict Biol       Date:  2019-08-23       Impact factor: 4.280

3.  Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system.

Authors:  Blandine Pommier; Françoise Beslot; Axelle Simon; Matthieu Pophillat; Toshimitsu Matsui; Valérie Dauge; Bernard P Roques; Florence Noble
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

4.  Sex differences in locomotor effects of morphine in the rat.

Authors:  Rebecca M Craft; James L Clark; Stephen P Hart; Megan K Pinckney
Journal:  Pharmacol Biochem Behav       Date:  2007-01-09       Impact factor: 3.533

5.  The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats.

Authors:  Mark J Millan; Laetitia Seguin; Alain Gobert; Didier Cussac; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

6.  Effects of mu- and kappa-2 opioid receptor agonists on pain and rearing behaviors.

Authors:  John K Neubert; Heather L Rossi; Jonathan Pogar; Alan C Jenkins; Robert M Caudle
Journal:  Behav Brain Funct       Date:  2007-09-20       Impact factor: 3.759

7.  Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use.

Authors:  Lisa L Wilson; Shainnel O Eans; Insitar Ramadan-Siraj; Maria N Modica; Giuseppe Romeo; Sebastiano Intagliata; Jay P McLaughlin
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.